What are the current challenges and protocols in Europe for making PCSK9 inhibitors an easily reimbursable, “mainstream” approach to managing patients with require secondary prevention for their high-risk ASCVD?

What are the current challenges and protocols in Europe for making PCSK9 inhibitors an easily reimbursable, “mainstream” approach to managing patients with require secondary prevention for their high-risk ASCVD?

What are the current challenges and protocols in Europe for making PCSK9 inhibitors an easily reimbursable, “mainstream” approach to managing patients with require secondary prevention for their high-risk ASCVD?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professor of Cardiology University of Oslo Oslo, Norway Visiting Associate Professorship Johns Hopkins University Baltimore, Maryland